Q BioMed (OTCMKTS:QBIO) Shares Down 2.6%

Shares of Q BioMed Inc (OTCMKTS:QBIO) dropped 2.6% during trading on Friday . The company traded as low as $1.73 and last traded at $1.82, approximately 82,918 shares traded hands during trading. A decline of 33% from the average daily volume of 124,511 shares. The stock had previously closed at $1.87.

Separately, Zacks Investment Research lowered Q BioMed from a “buy” rating to a “hold” rating in a research note on Friday, May 29th.

The stock has a 50 day simple moving average of $1.72 and a 200 day simple moving average of $2.01. The stock has a market cap of $41.32 million, a price-to-earnings ratio of -2.56 and a beta of 2.56.

Q BioMed (OTCMKTS:QBIO) last announced its quarterly earnings data on Wednesday, July 15th. The company reported ($0.11) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.13) by $0.02. The firm had revenue of $0.02 million during the quarter, compared to analyst estimates of $0.49 million. Sell-side analysts forecast that Q BioMed Inc will post -0.5 earnings per share for the current year.

About Q BioMed (OTCMKTS:QBIO)

Q BioMed Inc, a biomedical acceleration and development company, focuses on licensing, acquiring, and providing resources to life sciences and healthcare companies. The company offers Strontium Chloride SR89, a radiopharmaceutical therapeutic for the treatment of bone cancer pain therapies. It is also developing Man-01, a pre-clinical lead candidate for the treatment of primary open angle glaucoma; BM-001 for the treatment of rare pediatric nonverbal autism spectrum disorder; and Uttroside-B for liver cancer.

Further Reading: CD Ladder

Receive News & Ratings for Q BioMed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Q BioMed and related companies with MarketBeat.com's FREE daily email newsletter.